Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. by Vulcano M et al.
0014-2980/01/0303-812$17.50+.50/0 © WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2001
Dendritic cells as a major source of macrophage-
derived chemokine/CCL22 in vitro and in vivo
Marisa Vulcano1, Cristina Albanesi2, Antonella Stoppacciaro3, Renzo Bagnati1,
Giovanna D’Amico1, Sofie Struyf1, Pietro Transidico1, Raffaella Bonecchi1, Annalisa
Del Prete1, Paola Allavena1, Luigi P. Ruco3, Chiara Chiabrando1, Giampiero
Girolomoni2, Alberto Mantovani1,4 and Silvano Sozzani1
1 Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy
2 Istituto Dermopatico dell’Immacolata, IRCCS, Roma, Italy
3 Dipt. Medicina Sperimentale e Patologia, Universita` La Sapienza, Roma, Italy
4 Universita` di Milano, Milano, Italy
Macrophage-derived chemokine (MDC)/CCL22 is a CC chemokine active on dendritic cells
(DC), NK cells and Th2 lymphocytes. The present study was aimed at comprehensively
investigating MDC production in vitro and in vivo. DC were the most potent producers of
MDC among leukocytes tested. Endothelial cells did not produce MDC under a variety of
conditions. Signals that induce maturation (lipopolysaccharide, IL-1, TNF, CD40 ligand, rec-
ognition of bacteria and yeast) dramatically augmented MDC production, and dexametha-
sone and vitamin D3 blocked it. Prostaglandin E2, which blocked the acquisition of IL-12
production and the capacity to promote Th1 generation, did not affect MDC production.
Using mass spectrometry-based techniques, DC supernatants were found to contain N-
terminally truncated forms of MDC [MDC(3–69), MDC(5–69) and MD(C7–69)] as well as the
full-length molecule. In vivo, CD1a+, CD83+, MDC+ DC were found in reactive lymph nodes,
and in Langerhans’ cell histiocytosis. Skin lesions of atopic dermatitis patients showed that
CD1a+ or CD1b+ DC, and DC with a CD83+ phenotype were responsible for MDC production
in this Th2-oriented disorder. Thus, DC are the predominant source of MDC in vitro and in
vivo under a variety of experimental and clinical conditions. Processing of MDC to
MDC(3–69) and shorter forms which do not recognize CCR4 is likely to represent a feedback
mechanism of negative regulation.
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expressed and secreted DL: Dermatopathic lymphadeno-
pathy LCH: Langerhans’ cell histiocytosis
1 Introduction
Dendritic cells (DC) are professional APC that play a piv-
otal role in the initiation of specific immunity [1, 2]. Imma-
ture DC patrol nonlymphoid tissues and are very efficient
in taking up incoming antigens. In response to inflamma-
tory signals DC undergo maturation, a process during
which DC increase membrane expression of MHC and
co-stimulatory molecules and augment their ability to
activate T lymphocytes, including naive T cells [1–5]. A
necessary step in the induction of immunity is the migra-
tion of DC to lymphoid organs and spleen. In vivo migra-
tion of DC is controlled by a rapid and coordinated regu-
lation of chemokines and chemokine receptors during
DC maturation [3–5].
Macrophage-derived chemokine (MDC)/CCL22 [6] is a
CC chemokine produced in a constitutive way by macro-
phages and DC, and by activated B lymphocytes in vitro
[7–11]. MDC is chemotactic for DC, IL-2-activated NK
cells and chronically activated T lymphocytes [7–10]. It
binds to and activates CCR4, a chemokine receptor
shared with thymus- and activation-regulated chemo-
kine (TARC)/CCL17 [6,12], and preferentially expressed
by CD4+ and CD8+ lymphocytes with a Th2/Tc2 pheno-
type, and cutaneous lymphocyte-associated antigen
(CLA)+ T lymphocytes [13–15]. In circulating monocytes,
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Table 1. In vitro MDC production by different leukocyte subsetsa)
Experimental group DC Monocytes Macrophages B lymphocytes T lymphocytes NK
Control 45.8 ± 15b) 1.9 ± 2 8.1 ± 7 6.6 ± 1 1.0 ± 1 0.5 ± 0.1
LPS 102.6 ± 17 4.4 ± 1 ND ND ND ND
IL-4 ND 11.3 ± 6 50.0 ± 19 18.3 ± 4 2.8 ± 1 2.6±0.3
IL-13 ND 12.4 ± 9 30.2 ± 16 ND ND 2.0 ± 0.5
SACc) ND ND ND 16.5 ± 4 ND ND
Anti-CD3/anti-CD28 ND ND ND ND 15.0 ± 7 ND
IL-2 ND ND ND ND ND 0.8 ± 0.1
a) Cells were incubated for 48 h in the presence of the agonists.
b) MDC levels (ng/106 cells), evaluated by ELISA, are expressed as mean values ± SD of three to eight independent experiments.
c) Staphylococcus aureus Cowan strain.
MDC production is not constitutive but it can be induced
by Th2 cytokines such as IL-4 and IL-13, and down-
regulated by IFN- + , a prototypic Th1 cytokine [14, 16].
Chemokines, including MDC, can be processed by
CD26, a dipeptidylpeptidase expressed by endothelial
and epithelial cells, and activated T lymphocytes [17].
Chemokine truncation by CD26 results in no change,
loss or increase of their biological activity according to
the target chemokine [17]. MDC truncation by CD26
results in the production of proteins lacking two or four
N-terminal amino acids that have no ability to interact
with CCR4 [18].
Because of its regulation by IL-4 and IL-13, and the pref-
erential expression of CD26 by Th1 vs. Th2 cells, MDC is
believed to be part of a Th2 amplification loop and to
play a role in the selective migration of Th2 lymphocytes
in conditions such as atopic disorders and allergies, that
are largely mediated by these cells [19–21].
In vivo, MDC message expression is found in the thymus
and in lymph nodes [7, 22–24]. In mouse lymph nodes
MDC mRNA expression is confined to DC present in the
T cell areas [23]. CD11c+ cells purified from mouse lymph
nodes were also found to express MDC mRNA, with the
expression increased after in vitro maturation [9, 23]. No
data about in vivo MDC protein production are so far
available, and information about MDC expression in
human DC is scanty. The goal of the present study was
to comprehensively characterize the regulation of MDC
production in immature and mature human DC, and to
examine the expression of MDC protein in human patho-
logical conditions. Furthermore, a new analytical method
was developed to identify the presence of MDC pro-
cessed forms.
2 Results
2.1 MDC production by leukocytes
Table 1 shows that, as previously reported [7], DC and
monocyte-derived macrophages secrete MDC in the
absence of deliberate stimulation. LPS strongly up-
regulated the production in DC, while it was only a mod-
est activator in monocytes. IL-4 and IL-13 induced MDC
production in monocytes, monocyte-derived macro-
phages, in B lymphocytes and in NK cells. In T lympho-
cytes anti-CD3/anti-CD28 stimulation was the most
effective stimulation for MDC production. Neither resting
endothelial cells [human umbilical cord vascular endo-
thelial cells (HUVEC) and human microvascular endothe-
lial cell line (HMEC)] nor IL-4-, IL-13-, or IFN + -activated
HUVEC produced MDC (data not shown). These results
indicated that DC and macrophages are the most potent
MDC-producing cells in vitro.
2.2 MDC production during DC maturation
DC generated from monocytes secreted MDC with a rate
of production that declined by the end of the culture and
resulted in 95.5±50 ng/106 cells MDC (average ± SD;
range 24–170; n=10) on day 6. At this time, DC were
washed and incubated in the presence of 10 ng/ml LPS.
As shown in Fig. 1A and B, basal expression was
strongly up-regulated starting 90 min after stimulation
and increased up to 24 h. Accumulation of MDC RNA
was followed by protein secretion that peaked at 24 h
(Fig. 1C). At this time point the average concentration of
MDC present in the medium was 130±30 ng/106 cells
(range 40–300; n=13; Fig. 2B). Under the same experi-
mental conditions, TARC/CCL17, the CC chemokine that
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Fig. 1. Up-regulation of MDC, TARC, MIP-3 g and MCP-1 in
human monocyte-derived DC. (A) Northern blot analysis of
total RNA (10 ? g/lane) purified from DC stimulated with
10 ng/ml LPS. (B) Densitometric analysis of the autoradio-
graphs (24 h exposure) shown in (A). (C) ELISA determina-
tion of chemokines in the supernatants of DC shown in (A).
Fig. 2. MDC expression in mature DC. DC were stimulated with 20 ng/ml IL-1; 20 ng/ml TNF; 10 ng/ml LPS; CD40L (4:1) for 24 h.
(A) Monocyte-derived DC; (B) CD34+-derived DC. Cells were analyzed in Northern blot assays (top panels) as described above.
Supernatants were tested for MDC production by ELISA (bottom panels). Results are presented as average values of three (A) or
two (B) experiments.
shares the same receptor with MDC and is similarly regu-
lated in other cell types, was induced by LPS with com-
parable kinetics (Fig. 1A and B) and a mean protein level
of 204±50 ng/106 cells (n=3) at 24 h. On the other hand,
monocyte chemotactic protein (MCP)-1/CCL2 and mac-
rophage inflammatory protein (MIP)-3 g /CCL19, two
additional CC chemokines, were induced to a much
lesser extent at the message levels (Fig. 1A and B) and
MIP-3 g protein production was below the sensitivity of
the detection system used (1 ng/ml; Fig. 1C).
DC can be induced to acquire a mature phenotype by
stimulation with pathogen-derived agonists (LPS), pro-
inflammatory cytokines (IL-1 and TNF), and T cell-
derived signals (e.g. CD40 ligation) [1, 2]. Fig. 2A shows
that engagement of CD40, or incubation with LPS, TNF
or IL-1 had a comparable ability in inducing MDC synthe-
sis and release by maturing DC. Similarly, DC derived
from CD34+ cells showed a basal expression of MDC
that was also up-regulated by LPS, IL-1 or CD40 ligand
(CD40L; Fig. 2B, and data not shown). In addition, DC
readily produced very high levels of MDC and TARC,
moderate to high levels of regulated upon activation,
normal T cell expressed and secreted (RANTES), MIP-1 §
and IL-8, and low or negligible amounts of MCP-1
(Fig. 3). It is interesting to note that CD40 ligation, an
immune signal, is more effective in the induction of con-
stitutive chemokines than inflammatory chemokines.
Conversely, inflammatory signals, like LPS, are strong
inducers of both “classes” of chemokines.
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Fig. 3. Induction of constitutive and inflammatory chemoki-
nes by LPS and CD40 ligation in DC. DC were incubated in
the presence of 10 ng/ml LPS or CD40L (4:1, DC:transfect-
ants) for 24 h. Supernatants were evaluated for the presence
of chemokines by ELISA. Results are the average determi-
nations (± SD) of three independent experiments.
2.3 Regulation of MDC production
The ability of DC to induce naive T lymphocyte activation
may be altered by agents that interfere with cell matura-
tion or cytokine production. Corticosteroids, vitamin D3
and PGE2 exert multiple effects on DC functions and
share the ability to inhibit IL-12 production by these cells
[25]. Interaction of DC with T cells in the absence of IL-12
may support the generation of a Th2-skewed response
Table 2. Modulation of MDC production by inhibitors of IL-12 production in DCa)
Experimental group MDC (ng/ml) IL-12 (pg/ml) CD83 (% inhibition)b)
Control 97 ± 12d) X 40 ND
LPS 205 ± 17c) 250 ± 59c) 0
LPS + dexamethasone 105 ± 11d) X 40 60 ± 8c)
LPS + vitamin D3 122 ± 17d) X 40 58 ± 15c)
LPS + PGE2 200 ± 15c) 96 ± 21 0
a) Immature DC (106/ml) were exposed to 10 ? M dexamethasone, 10 ? M PGE2, 1 ? M vitamin D3 for 6 h before stimulation with
100 ng/ml LPS for 48 h. Results are the average numbers ± SD of three to five independent experiments. MDC levels were
evaluated by ELISA.
b) % of inhibition of mean fluoresence channels with respect to LPS values.
c) p X 0.05 vs. control by paired Student’s t-test.
c) p X 0.05 vs. LPS by paired Student’s t-test.
[26]. Table 2 shows that dexamethasone and vitamin D3
decreased MDC production induced by LPS. On the
contrary, PGE2 did not have a statistically significant
effect. As expected dexamethasone and vitamin D3,
but not PGE2, inhibited DC maturation as assessed by
CD83 induction (Table 2). Therefore, MDC production by
maturing DC is apparently correlated with cell maturation
but not with IL-12 production.
Immature DC take up antigens by multiple mechanisms
[1, 27]. To evaluate whether these pathways could
induce MDC production, DC were incubated in the pres-
ence of dextran (mannose receptor mediated), albumin
(fluid phase pinocytosis) or opsonized zymosan (FcR
mediated). Fig. 4 reports that neither the uptake of dex-
tran nor that of albumin induced per se MDC secretion.
In contrast, phagocytosis of opsonized zymosan, a
strong cell activator signal [28], was as effective as LPS
in inducing MDC production (Fig. 4). Additionally, two
prototypic pathogens, OK432 (gram-positive bacteria),
and Candida albicans, were as strong as LPS in inducing
MDC release (Fig. 4).
2.4 Presence of MDC and its N-terminally
truncated forms by HPLC-MS/MS
The biological activity of MDC is strictly dependent on an
intact N terminus. Truncation of the protein by proteolytic
enzymes, including CD26, hampers the interaction of the
protein with CCR4, the only known MDC receptor [12].
Since all available ELISA cannot discriminate the differ-
ent MDC forms, we devised a novel HPLC-MS/MS
assays for such measurements. As reported in Fig. 5A,
this technique allowed to discriminate among the differ-
ent molecular masses of full-length and truncated pro-
teins in a quantitative way. Different amounts of full-
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Fig. 4. Role of endocytosis in MDC production by DC. DC
were cultured in the presence of 1 mg/ml dextran; 1 mg/ml
albumin; opsonized zymosan (OZA; 200 ? g/ml); OK432
(100 ? g/ml); C. albicans (100 ? g/ml) for 24 h and then tested
by ELISA for their ability to release MDC. Average numbers
(±SD) of three to seven independent experiments are
reported.
Fig. 5. Detection of MDC and its truncated forms by HPLC-
MS/MS with ion spray ionization analysis in immature and
mature DC supernatants. (A) MS/MS spectra of MDC pro-
teins. The spectra were obtained by fragmentation of the
parent [M + 7H]7+ ions (m/z 1172, 1156, 1134, 1103) of the
different MDC forms. The m/z 604 product ion is common to
all forms and corresponds to a triply-charged y fragment
(y153+). The other product ions (m/z 1598, 1570, 1531, 1476)
are the complementary quadruply-charged b fragments
(b554+, b544+, b524+, b504+). (B) Relative presence of intact and
truncated forms of MDC in the supernatants of immature
and LPS-maturated DC (n=4). Total MDC concentration
(100%), as assessed by ELISA, was 64±24 ng/ml and
168±39 ng/ml (n=4) for immature and mature DC, respec-
tively. The equivalent figures obtained by HPLC-MS/MS
(sum of the different forms) were 54±14 ng/ml and
189±28 ng/ml, respectively.
length and truncated proteins were present in DC super-
natants at 48 h (Fig. 5B). MDC(1–69) and MDC(3–69)
were the two predominant forms, representing 30 and
59% of the total protein, respectively. Limited amounts
of MDC(5–69) and MDC(7–69) were also detected, mak-
ing up 2.3 and 5.9% of total MDC, respectively (Fig. 5B).
MDC levels (ng/ml) measured by ELISA (y) were strongly
correlated with the sum of all MDC forms measured by
HPLC-MS/MS (x) (r=0.88, p X 0.004; n=8; y=10+0.9x).
This result was expected, given the 100% cross-
reactivity of the ELISA antibody against N-terminally
truncated forms of MDC.
2.5 Expression of MDC in human tissues
In all sections from normal human tissues (skin, lung,
intestine, thyroid, salivary glands, thymus and lymph
nodes) but thymus and lymph nodes, MDC+ cells were
absent. In the thymus, immunostaining for MDC was
detected in medullary epithelial cells and in DC as previ-
ously reported [24] (data not shown).
In human lymph node reactive hyperplasia, MDC+ cells
were confined to the T cell-dependent paracortical area,
the same area where also CD1a+ Langerhans’ cells and
CD83+ DC localize (Fig. 6A, top panels a, b, c). Similar to
Langerhans’ cells, they show dendritic morphology and
form rosettes with the nearby lymphocytes (Fig. 6A,
panel d). Double staining experiments showed that
MDC+ cells constituted a subset of CD1a+ cells (mean:
57%; range: 23–68%) and of CD83+ cells (mean: 21%;
range: 18–37%; Fig. 6A, panels e and f). No CD68+ cells,
a marker for macrophages, were found to express MDC
(data not shown). Therefore, MDC production in tissues
is confined to a mature subset of Langerhans’ cells.
Subsequent experiments evaluated MDC production in
two pathological conditions characterized by accumula-
tion of Langerhans’ cells, namely dermatopathic lymph-
adenopathy (DL), and Langerhans’ cell histiocytosis
(LCH). DL is a pathological condition characterized by
the massive accumulation of CD1a+/CD83+ Langerhans’
cells in the lymph node paracortex (Fig 6B, panels b
and c). LCH is a pathological condition characterized by
tissue localization of CD1a+/CD83+ Langerhans’ cells
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Fig. 6. Expression of MDC in human lymph node reactive hyperplasia (LNRH), dermopathic lymphadenopathy (DL), and Langer-
hans’ cell histiocytosis (LCH). (A) LNRH: MDC immunostaining shows scattered cells located in the paracortex (a) that can form
rosettes with lymphocytes (d). MDC+ cells localize in the same area of CD1a Langherans’ cells (b) and CD83+ DC (c). Section of
LNRH were double stained for MDC (red color) and CD1a (e) or CD83 (f) (black color). MDC co-localizes with CD1a, and CD83
in DC of the paracortex. (B) DL: MDC+ cells are few and scattered in the residual normal paracortex (a). The paracortex is partially
effaced by the accumulation of CD1a+- (b), and CD83+- (c) MDC negative Langerhans’ cells (a). LCH: The majority of the Langer-
hans’ cells express MDC (d) as shown by CD1a (e) and CD83 (f) staining of contiguous sections. Avidin-biotin-horseradish perox-
idase complex developed with 3–3’diaminobenzidine, counterstained with haematoxylin. 400x, or 1000x (panels e and f) enlarg-
ments. PC = paracortex; MZ = mantle zone; GC = germinal center.
(Fig. 6B, panels e and f). Fig. 6B shows that Langerhans’
cells present in LHC, but not those present in DL, were
positive for MDC expression (panels d and a, respec-
tively).
Tissue sections from normal human skin, chronic atopic
dermatitis lesional skin, positive patch test reaction to
nickel and chronic psoriasis lesions were also evaluated.
MDC expression was absent in normal skin (Fig. 7A).
Conversely, MDC-positive cells were observed in sec-
tions from atopic dermatitis (Fig. 7B-E), allergic contact
dermatitis skin (Fig. 7F-H) and psoriasis, in both the epi-
dermis and dermis. Double staining showed that the
cells positive for MDC were mostly a subset of CD1a+
(4.4–10.1%) or CD1b+ (9.1–30.5%) cells, and a higher
percentage of CD83+ DC, especially in atopic dermatitis
skin (35.2%; Table 3). Only a minority (3.2–4.4%) of
CD14+ cells were stained by anti-MDC mAb. Very few
MDC-expressing cells were T cells, with less than 2% of
CD3+ being also positive for MDC in all the skin diseases
studied (data not shown). No B cells and scanty CD56+
cells (NK cells) could be detected in skin sections, and
they were not investigated for MDC co-expression. Thus,
MDC production in lesional skin appears to be confined
to DC, and particularly to DC with a mature phenotype
(CD83+), with only a minor contribution of CD14+ mono-
cytes and even less of T lymphocytes. It should be
noted, however, that only a portion (18.6–35.2%) of
mature DC expressed MDC, a finding possibly related to
the different maturational stages of infiltrating DC. Atopic
dermatitis presented a higher number of CD1a+ and
CD1b+ DC, and of mature CD83+ DC, as well as a higher
percentage of MDC+ cells compared to allergic contact
dermatitis and psoriasis (Table 3).
3 Discussion
This study investigates the regulation of MDC/CCL22
production by leukocytes in vitro and in vivo, and pro-
vides three main new findings. First, DC are the major
producers in vitro, and probably the unique leuko-
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Fig. 7. Expression of MDC in atopic dermatitis and allergic contact dermatitis. Sections from normal human skin (a), atopic der-
matitis (b-e) and allergic contact dermatitis (f-h) were double stained for MDC (red color) and CD1a (a, b, f), CD83 (c and g), CD1b
(d and h) or CD14 (e) (blue color). In panels c, e, f and h arrows indicate the double positive cells. Bars, 25 ? m.
cyte subsets to produce MDC in vivo (Table 1, 3, and
Fig. 6, 7). Second, MDC production is mostly associated
with the mature CD83+ DC phenotype both in vitro and in
vivo. However, in vivo, also CD83– DC can express MDC
protein (Fig. 6B, D-F). Third, DC supernatants contain
MDC both as intact protein and as truncated forms, as
assessed by a new analytical method.
Table 3. MDC expression in cells of the DC or monocyte lineage in Th2- and Th2-mediated skin diseasesa)
MDC+/CD1a+ MDC+/CD83+ MDC+/CD1b+ MDC+/CD14+
Normal skin (n = 3) 1 ± 1/176 ± 20 1 ± 1/12 ± 4 0/70 ± 10 0/70 ± 12
Atopic dermatitis (n = 5) 42 ± 6/418 ± 32 44 ± 5/125 ± 15 39 ± 6/128 ± 10 7 ± 2/220 ± 16
(10.1 %) (35.2 %) (30.5 %) (3.2 %)
Allergic contact dermatitis (n = 4) 12 ± 3/272 ± 18 8 ± 2/42 ± 4 6 ± 3/76 ± 8 5 ± 2/138 ± 11
(4.4 %) (19 %) (9.1) 3.6 %)
Psoriasis vulgaris (n = 3) 18 ± 4/330 ± 32 11 ± 3/59 ± 7 ND 7 ± 3/160 ± 21
(5.4 %) (18.6 %) (4.4 %)
a) Skin sections were double stained for MDC and the indicated membrane markers. Slides were analyzed blind by two
observers and positive cells were counted with an eyepiece graticule at a magnification of 200 ×. For each biopsy, two
sections were stained for each mAb and positive cells were evaluated in ten adjacent fields. Results are expressed as the
mean number ± SD (and percentage) of double-positive on surface marker positive cells.
In DC, production of MDC was biphasic, the first phase
being present during the differentiation of monocytes to
immature DC, and the second phase being induced by
signals able to drive DC maturation. This finding con-
firms previous reports in which MDC expression was
evaluated at the mRNA level [7, 22, 23], and extend them
showing that MDC is, together with TARC, the most
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abundant chemokine produced by DC with over 100 ng/
106 cells released in 24 h. In fact, other inflammatory
chemokines, such as RANTES, MIP-1 § and IL-8 are pro-
duced in lower amounts, while MCP-1 and MIP-3 g were
released at very low levels. When different leukocyte
populations were compared for their ability to release
MDC in vitro, DC appeared the most relevant producers,
followed by monocyte-derived macrophages G mono-
cytes G B lymphocytes G T lymphocytes G Th2 and Th1
polarized cells (Table 1 and [29]). CCR4 is also up-
regulated in mature DC [30], suggesting a role for MDC
and TARC in co-localization and interaction of DC and T
lymphocytes. Another chemokine produced by immature
DC and up-regulated during maturation is fractalkine.
Unlike MDC, in DC fractalkine is not induced by inflam-
matory stimuli (e.g. LPS and TNF) and it is almost exclu-
sively up-regulated by CD40L [31] in migratory murine
skin DC. Since fractalkine is active on activated T lym-
phocytes, but not on DC, it is tempting to speculate that
the expression of fractalkine and MDC by mature DC is
not redundant and might promote different cell-to-cell
interactions.
All the maturation signals tested in vitro, including LPS,
C. albicans, gram-positive bacteria (OK432), IL-1 and
TNF, induced MDC production. Similarly, phagocytosis
of opsonized zymosan, an event known to induce pro-
duction of pro-inflammatory cytokines (e.g. IL-1 and
TNF) [28] induced levels of MDC comparable to those
observed with LPS. On the contrary, endocytosis of dex-
tran and albumin per se were not effective in inducing
MDC production. Inhibition of LPS-induced DC matura-
tion by dexamethasone and vitamin D3 resulted in a
reduced production of MDC. On the contrary, PGE2
treatment, which does not inhibit DC maturation, had no
effect on the release of this chemokine.
HPLC-MS/MS analysis of MDC in the supernatants of
immature and mature DC revealed that the protein is
present in different molecular forms. Full-length (1–69)
MDC as well as its truncated forms, devoid of two (3–69),
four (5–69) or six (7–69) amino acids were detected, with
MDC(3–69) and MDC(1–69) being the predominant
molecular species. Maturation of DC with LPS did not
change the relative proportion of the truncated forms.
The membrane dipeptidylpeptidase CD26 can generate
truncated forms of MDC (3–69 and 5–69) in vitro. A fur-
ther processed form of MDC (9–69) was purified from the
supernatant of a CD8+ T cell clone, suggesting the
involvement of additional proteases in MDC processing
[32]. MDC(3–69) and MDC(5–69) lack the ability to bind
and activate CCR4, therefore they are inactive on T lym-
phocytes and DC but surprisingly retain chemotactic
activity for human monocytes [18]. If the data presented
in this study reflect an in vivo situation, it means that
some of the MDC produced by DC may be directed to
monocytes (effectors of a Th1 response) rather than to
Th2 cells. The assays currently available (e.g. ELISA,
immunohistochemistry or mRNA measurements) do not
allow to discriminate between intact and truncated forms
of MDC. Therefore, the availability of this new technique
to detect N-terminally processed proteins provides a
new tool to elucidate the role of chemokines in vivo.
Immunohistochemical analysis showed that under nor-
mal conditions, MDC expression is confined only to
lymph nodes and thymus. In reactive lymph node hyper-
plasia, as well as in skin affected by atopic dermatitis,
allergic contact dermatitis or psoriasis, MDC-positive
cells were mostly CD1a+ or CD1b+ DC, and many of them
expressed a CD83+ mature phenotype. In contrast, only
a minority of CD14+ or CD68+ cells and very few CD3+ T
lymphocytes were stained by anti-MDC mAb. Thus, also
in vivo, DC seem to be the major MDC-producing cell
population. CD1a+ and CD83+ mature DC are found
increased in LCH and DL [33]. However, MDC-producing
cells were observed only in the former situation. LCH,
but not DL, is characterized by a massive local produc-
tion of inflammatory cytokines (GM-CSF, TNF, IL-1, IL-2,
IL-4, IL-5 and IFN) [34,35]. This finding strongly suggests
that also in vivo, MDC production is not exclusively asso-
ciated with a mature DC phenotype but may be regu-
lated by the local cytokine context.
Atopic dermatitis is a pathology characterized by an
abundant infiltrate of Langerhans’ cells and DC with the
features of monocyte-derived DC [36]. Although in lower
numbers, MDC-positive DC were also detected in lesio-
nal biopsies of psoriasis and allergic contact dermatitis
to nickel. Atopic dermatitis is associated with a predomi-
nant expansion and activation of Th2 cells whereas aller-
gic contact dermatitis and psoriasis are primarily Th1-
mediated diseases [11, 37]. These data indicated that
MDC production, without being an exclusive character-
istic of atopic disorders, is preferentially associated with
a Th2 rather than a Th1 lymphocyte infiltrate. Recently
it was shown that atopic dermatitis patients have
increased levels of circulating MDC compared to
patients suffering from Th1-dominated disorders or con-
trol subjects [38]. Moreover, in the atopic dermatitis-like
lesions of NC/Nga mice MDC is expressed by dermal DC
[39]. MDC is chemotactic for T lymphocytes that express
the skin homing receptor, CLA [15]. Thus, MDC
expressed by CD83+ DC in the skin may function to
recruit CCR4+ lymphocytes in chronically inflamed skin.
Collectively, these results indicate that CD1a+ and CD83+
DC are the main cells that produce MDC both in vitro and
in vivo when exposed to an appropriate cytokine mic-
roenviroment. The possibility to detect cleaved forms of
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the protein in crude supernatants, and possibly in bio-
logical fluids, will be instrumental to investigate the regu-
lation of this chemokine by proteases and in particularly
by CD26, an enzyme preferentially expressed by Th1
lymphocytes.
4 Materials and methods
4.1 Cytokines and reagents
GM-CSF was a gift from Novartis (Milan, Italy). Human IL-13
was a gift from Dr. A. Minty, Sanofi Elf Bio Recherches
(Labe`ge, France). Human TNF- § and IL-1 g were from BASF/
Knoll (Germany) and Chiron (Milan, Italy), respectively. All the
other reagents were from Sigma (St. Louis, MO) and were
endotoxin free. OK432, a lyophilized preparation of attenu-
ated Su strain (group A, type 3) of Streptococcus pyogenes
was a gift from Chugai Pharmaceutical Co. Ltd. (Tokyo,
Japan). Heat-inactivated C. albicans was from ATCC (Rock-
ville, MD).
4.2 Leukocyte preparation
DC were generated in vitro as previously described [40] by
incubating blood monocytes with 50 ng/ml GM-CSF and
20 ng/ml IL-13. DC were also prepared from purified cord
blood CD34+ cells [41]. DC maturation was achieved in the
presence of 10 ng/ml LPS, 20 ng/ml TNF or 20 ng/ml IL-1
for 24 h, or as otherwise specified. CD40L-transfected
J558L cells or mock-transfected control cells were cultured
with DC at a 1:4 ratio. Macrophages were derived from fresh
monocytes cultured with 1000 U/ml M-CSF for 8 days. Total
T cells were separated from buffy coats by Ficoll gradient. T
cells (106/well) were cultured in 24-well flat-bottom plates
pre-coated with anti-human CD3 mAb (5 ? g/ml, OKT3) plus
anti-human CD28 mAb (1 ? g/ml, PharMingen, San Diego,
CA), overnight. Supernatants were collected after 48 h. NK
cells were obtained as previously described [42].
4.3 Northern blot analysis
Total RNA was extracted by the guanidinium thiocyanate
method, blotted and hybridized as described [40]. The
MDC- and MCP-1/CCL2-specific probes were obtained
as described [7]. The human full-length MIP-3 g /CCL19-
specific probe was excised from EST clone W05519 (IMAGE
Consortium, Research Genetics, Huntsville, AL) with NotI
and EcoRI. The TARC/CCL17-specific probe was obtained
by reverse transcription-PCR amplifying the full-length
cDNA reported sequence (AA175762) with specific primers
(5’-ATGGCCCCACTGAAGATGCTGGCC-3’ and 5’-TCAA-
GACCTCTCAAGGCTTTGCAG-3’), and confirmed by se-
quencing.
4.4 ELISA
The MDC ELISA based on antibodies generously provided
by Dr. P. A. Gray (ICOS, Bothell, WA) was previously
described [16]. The antibodies cross-reacted 100% with
truncated forms of MDC, MD(C3–69) and MDC(5–69). Sand-
wich ELISA for TARC and MIP-3 g (R<ISO>D Systems, Min-
neapolis, MN), RANTES/CCL5 (Amersham) and MIP-1 § /
CCL3 (Endogen) were used. ELISA for IL-8 and MCP-1 were
previously described [43].
4.5 Analysis of MDC and its truncated forms
by HPLC-MS/MS
DC supernatants were spiked with internal MDC(0–69) stan-
dard, lyophilized, reconstituted with water/acetonitrile 1:1,
and acidified to pH 6 with 1 N formic acid. Samples were
then analyzed by HPLC-MS/MS. Control samples run in par-
allel showed that the presence of 10% FCS in the incubation
medium did not change the relative amount of truncated
forms of MDC recovered at the end of the incubation time
(48 h; data not shown). Analysis of MDC forms was per-
formed with a newly developed method using a PE Sciex
API 3000 triple quadrupole instrument, interfaced with
Perkin-Elmer Series 200 micro LC pumps and a TurboIon
Spray source operated in the positive ionization mode (Bag-
nati et al., in preparation). MS source conditions were set to
maximize analyte signals and a collision energy of -46 eV
was used for fragmentation by collision-activated dissocia-
tion (CAD). For each compound, two MS/MS transitions
from the precursor ion [M + 7H]7+ to its two major product
ions (Fig. 5A) were simultaneously monitored: m/z 1172 - G
1598 and 1172 - G 604 for MDC(0–69), m/z 1156 - G 1570
and 1156 - G 604 for MDC(1–69), m/z 1134 - G 1531 and
1134 - G 604 for MDC(3–69), m/z 1103 - G 1476 and 1103 - G
604 for MDC(5–69).
4.6 Immunohistochemistry
Normal lung (n=3), intestine (n=2), thyroid (n=5), salivary
glands (n=2), thymus (n=2) and lymph node reactive hyper-
plasia (n=4) specimens were obtained from routine surgery
(University of Brescia, Italy). Punch biopsies of normal skin
(n=3), chronic atopic dermatitis lesional skin (n=5), 48-h
patch test reactions to nickel (n=4) and psoriasis lesions
(n=3) were obtained at IDI (Rome, Italy). Single stainings
were performed with mAb against: MDC mAb clones 272D
and 272Z [24], CD1a, CD86 (PharMingen), CD83 (Immuno-
tex, Marseille, France), CD68 and CD14 (Becton and Dickin-
son, Mountain View, CA), developed with ABC kit (Vector
Laboratories), stained with 0.03% H2O2 and 0.06% 3–3’dia-
minobenzidine (Dako) in PBS and counterstained with
hematoxylin. Double immunostaining was performed with
the same anti-MDC mAb and mAb anti-CD1a (1:20), anti-
CD1b (1:30), anti-CD83 (1:10), anti-CD14 (1:10) or anti-CD3
(1:20), using avidin-biotin-peroxidase or avidin-biotin-
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alkaline phosphatase systems (Vector Laboratories). 3-
amino-9-ethylcarbazole and Blue Vector (Vector Laborato-
ries) were used as chromogens to reveal the peroxidase and
alkaline phosphatase activities, respectively. No counter-
stain was applied. For each biopsy, two sections were
stained for each mAb and positive cells were evaluated in
ten adjacent fields.
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